Kiora Q1 net loss $2.2M; cash $24.1M into late 2027; initiates two Phase 2 trials

KIORA PHARMACEUTICALS INC

2025-Q1 EPS reported -$0.52

Net loss $2.2M vs net income $13.4M in Q1 2024 due to $16M upfront from Théa in prior year.
Cash & short-term investments $24.1M; runway extended into late 2027 beyond key data readouts.
Initiating Phase 2 KLARITY trial for KIO-104 (retinal inflammation) and ABACUS-2 for KIO-301 (retinitis pigmentosa); first patient enrollment expected Q2 2025.
Received $1.8M in reimbursed Q4 2024 R&D expenses from Laboratoires Théa; total $5.6M since collaboration began.
R&D expenses $2.5M (up from $1.7M) due to clinical trial activities; G&A $1.5M up from $1.3M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.